Camille N Abboud MD

Hematologic Oncology

Professor of Medicine Section BMT and Leukemia

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Summary

Dr. Camille Abboud is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 43 years. He also speaks multiple languages, including French and Arabic. He specializes in hematologic oncology and is experienced in hematologic oncology, acute myeloid leukemia, hairy cell leukemia, lymphoma, and cellular therapy including marrow and peripheral blood stem cell transplants and CAR-T treatment of lymphoma, myeloma and Acute Lymphoblastic Leukemia.

Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1974 - 1976
American University of Beirut Faculty of MedicineClass of 1974

CMS Meaningful Use Stage Stage 1 Certification Follow My Health, Jardogs, 2012, 2014, 2016-2017
CMS Meaningful Use Stage Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2012, 2014, 2016-2017
CMS Meaningful Use Stage Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012, 2014, 2016-2017

PubMed

1 citations
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.
Gabriel N Mannis, Camille N Abboud, Naval G Daver, Guru Subramanian Guru Murthy, Eunice S Wang
Ejhaem. 2025-06-01
3 citations
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2025-03-27
9 citations
Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10

Journal Articles

Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
Camille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SEL120 _ a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinica...
Camille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia
Camille Abboud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Siteman Cancer Center to Open North St. Louis County Location July 1June 30th, 2017
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationAugust 25th, 2023